August 20171

ORAL DELIVERY PLATFORM FOR TREATING AQUACULTURE DISEASES

IMPORTANT NOTICE

This presentation has been prepared by ViAqua Therapeutics Ltd. (the “Company”) solely for informational purposes. The information contained herein has been prepared to assist prospective investors in making their own evaluation of the Company and does not purport to be complete or to contain all of the information a prospective or existing investor may desire. In all cases, interested parties should conduct their own investigation and analysis of the Company and the data set forth in this information. The Company has prepared this presentation based on information available to it, including information derived from public sources that have not been independently verified. The Company makes no representation or warranty as to the accuracy or completeness of this information and shall not have any liability for any representations (expressed or implied) regarding information contained in, or for any errors omissions in, this presentation. This presentation includes certain statements and estimates provided by the Company with respect to the projected future performance of the Company. Such statements, estimates and projections reflect various assumptions by management concerning possible anticipated results, which assumptions may or may not be correct. No representations are made as to the accuracy of such statements, estimates or projections. This presentation may contain statements that are not historical facts, referred to as “forward looking statements.” The Company’s actual future results may differ materially from those suggested by such statements. No assurance can be given that future events will occur or that projections will be achieved. Past performance is not a reliable indication of future performance. This presentation is not, and nothing in it should be construed as, an offer, invitation or recommendation in respect of the Company’s securities, or an offer to sell, or a solicitation of an offer to buy, the Company’s securities in any jurisdiction. Neither this presentation nor anything in it shall form the basis of any contract or commitment. Prospective investors should not construe the contents of this presentation as business, legal, tax, investment or other advice. Each prospective investor should make his, her or its own inquiries and consult his, her or its own advisors as to the appropriateness and desirability of an investment in the Company and as to business, legal, tax and related matters concerning an investment in the Company.

An investment in the Company shall be allowed only to such number and category of investors in accordance with applicable laws and regulations and pursuant to a predetermined process. Accordingly, detailed information in connection with the investment shall be revealed and delivered only to a limited number of qualifying investors as provided by law.

LEGAL DISCLAIMER

ANNUAL GROWTH RATEfor the past decade

SHELLFISH MARKET

10%Asia 89%Americas 10%Africa 0.2%

China 42%Indonesia 23%Vietnam 14.5%India 11.5%Thailand 8.7%

BYCONTINENT

ASIA

Shrimp aquaculture production by major producers in Asia (2016, FAO and GOAL Surveys)

Shrimp aquaculture production(2016, FAO and GOAL Surveys)

Shellfish aquaculture has become one of the fastest growing animal production industries in the world.

$17B MARKET VALUE PER YEAR

3

SHELLFISH AQUACULTURE

DISEASE =BIGGEST RISK(FAO 2016)

Undermines market development

4

SHRIMP INDUSTRY LOSSES

What can we do about it today?

April 2014

Jan. 2015

5

March. 2017

Quote

NO CURRENT TREATMENT!

Today, there are no means to prevent or treat viral diseases in shrimp. When a disease appears, it wipes out the pond within 7-10 days.

6

INNOVATIVE APPROACH

7

RNA INTERFERENCE Therapeutic approach: silencing key genes of a virus using a method called RNA interference (RNAi)

This process is similar to vaccination.

1 RNA delivered to the cells

2 VIRAL RNAis marked, then triggers cell to react

3 VIRAL RNAis destructed

RNA acts as a TARGET DESIGNATOR. It marks the viral RNA and tells the cell it has an intruder and should prepare to fight it.

8

RNAi VERY PROMISING APPROACH FOR TREATING SHRIMP VIRUSES

Injecting the shrimp one by one is not a feasible method for wide use in shrimp aquaculture.

RNAi has very promising results on shrimp viruses when tested with injection. But try to treat 20 tons of shrimps, one-by-one, using a syringe.

9

FEEDDELIVERY BY

ViAqua Platform Technology Tailored for Aquaculture

DELIVERYTHE REAL CHALLENGE

10

THE CONCEPT NANOPARTICLE CARRIER

• Non-GMO• Non-hormonal• No antibiotic component• Feed-grade formulation• Safe for both shrimp and

humans• Can effect multiple virus

strains per treatment

For each virus, we (1) select and produce an effective RNA sequence, and (2) combine the RNA strands with our specially developed carrier.

11

Aquatic Environment Digestive System Cell Membrane

THE ENTIRE PROCESS

pass from the aquatic environment, through the digestive system and ...

into the cells where the RNA is released and triggers the protection response.

Nanoparticles (NPs) are integrated into feed...

12

RESULTSTEST

13

SUCCESSFUL TRIALS INJECTED VIAQUA NPs1

UntreatedViAqua

Survival %

87% - 93% 0%ArizonaTrial

+

ThailandTrial

99% 0%++

Challenge tests against the WSSV virus performed at two different facilities (Arizona and Thailand) showed that injected ViAqua RNA sequences and ViAqua formulated nanoparticles are highly effective against the virus.

14

2 OVERCOME KEY CHALLENGES AQUATIC CONDITIONS

ViAqua nanoparticles are stable in the sea and freshwater aquatic environments

15

3 VIAQUA NPs IN THE DIGESTIVE SYSTEM

• Carrier protects RNA from enzymatic degradation in digestive system• NPs absorbed through digestive system to induce desired response to virus

This image shows the absorption of the nanoparticles into the shrimp cells.

16

4 LAB TESTS INTUBATION INTO DIGESTIVE SYSTEM%

Gen

e ex

pre

ssio

n

ViAqua nanoparticles (NPs), intubated into shrimp digesting system, enter the shrimp cells and trigger the RNAi reaction; tests showed 60-70% gene silencing of the target gene.

17

Control no dsRNA

Injection NP1 NP2

90% 70% 60% % Gene Silencing0%

NP = nanoparticle formulation (intubated)

100

80

60

40

20

VIAQUA ADVANTAGES

Cost effective 2-3 administrations per life cycle;

estimate 3%-5% increase in total feed price

Delivery platform enables treating wide range of viruses in shrimp and other shellfish species

Know-how enables developing oral delivery for improved fish vaccines

First real solution No treatment to date for shrimp aquaculture diseases

Simple mass administration via feed No addition to work flow

Feed-based components for shorter regulatory process

18

TEAM OF EXPERTS

Shai Ufaz, Ph.D.CEO & Co-FounderMolecular biologist; experience in biotechnology, genetic engineering, protein expression; project manager, ProtalixBiotherapeutics, TransAlgae; Ph.D., plant genetics

Shai Einbinder, Ph.D.Co-FounderMarine biologist; experience in product development, management; VP Development & Projects, TransAlgae; CEO, Aurora-V; Ph.D., marine biology

Prof. Avi Schroeder, Chief ScientistExtensive development in fields of RNA delivery and nanotechnology; Ass’t. Prof. of Chemical Engineering, Technion-Israel Institute of Technology; postdoctoral fellow with Prof. Robert Langer, MIT

19

CompanyAcquirer/

License

Deal

TypeYear

App. Deal

Size

Harris Vaccines MERCK Acquisition 2015 NAVaccines animals and

aquaculture

PHARMAQ Zoetis Acquisition 2015 $765 M Aquaculture

Beeologics Monsanto Acquisition 2011 $130 M RNAi technology plants

Rosetta Green Monsanto Acquisition 2013 $37 MRNAi technology

plants/Algae

Devgen Syngenta Acquisition 2012 $522 M RNA plants

RNAi, VACCINES DRIVING M&A ACTIVITY

20

IP STATUSUS Patent ApplicationNo. 62/327,605 Filed on 26 April 2016 ViAqua Therapeutics Ltd. Inventors: Shai UFAZ et al.

TITLE: COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS IN SHRIMPS

All the technology presented here was filed in a PCT application in April 2017.

21

Quote

22

MicroSynbiotix TransAlgae ViAqua

Technology Transgenic algaeTransgenic algae (protein based drugs, bio-molecules)

Particle formulation

Application AquacultureAquaculture, animal healthcare, crop protection

Aquaculture

Development stage R&D R&D R&D

AdvantagesMaterials produced inside delivery platform; no need for formulation

• Flexible design tailored for delivery of the active material

• High production yield of active material• Not dependent on unstable biological

processes• Smoother regulatory process

Drawbacks

• Difficult to make changes to algal cell to improve delivery• Dependent on biological process (contamination, temperature

changes)• Concentration of active material limited to production yield of

material inside the algae• GM Algae - regulatory issues

Formulation of active material required following production

COMPETITORS DEVELOPING ORAL DELIVERY

23

BUSINESS MODEL

ViAqua

• Produce dsRNA + carrier = proprietary nanoparticles

• Sell ViAqua NPs to partner(s)

ViAqua + feed/animal health companies partner to

• Develop feed formulation

• Prepare for mass production

Partner (feed/animal health company)

• Manufacture ViAqua “medical” feed

• Market and sell medical feed via their established distribution/sales networks

Future

• ViAqua to explore licensing its technology to additional feed/animal health companies

• Second product development: oral delivery platform for fish vaccines

24

SALES FORECAST ASSUMPTIONS

• Based on feedback from market players +growers

• Aquaculture farmers today spend approximately 2.5% of revenues on vaccine/disease treatment

• Growers willing to pay up to 10% above feed price for specialty/treatment

• First sales ~Q2 2021

25

DEVELOPMENT MILESTONES

2017 2018 2019 2020

Milestones Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1

60% survival rate in WSSV challenge test using orally delivered dsRNA

80%-90% survival rate in WSSV challenge test using orally delivered dsRNA – lab scale 80%-90% survival rate in WSSV challenge test using orally delivered dsRNA – field trial

26

WHY VIAQUA?

• Highly experienced team

• Experience in working with different delivery platforms, including algae (competitive technology)

• Unique combination of strong backgrounds in multiple disciplines

• Selected chemical engineering approach – enables tailoring exact formulation for oral delivery to shrimp

• Non GMO solution – simpler, faster regulatory path to approval

• Support from the Technion- Israel Institute of Technology – access to extensive knowledge base + state-of-the-art equipment

BRINGING A DESPERATELY NEEDED TREATMENT FOR AQUACULTURE DISEASESContactShai UfazMobile: +972-52-843-0591Email: shai.u@viaqua-t.com

27